20161122_mc2-portrait-04

Latest News:

MC2 Therapeutics A/S announces positive top-line results from Phase 3 clinical trial comparing MC2-01 Cream to Taclonex® in adults with psoriasis

POSTED: August 21, 2018

MC2-01 Cream demonstrates statistically significant superiority in both treatment success and patient reported treatment convenience compared to Taclonex® Topical Suspension. Both primary and secondary endpoints were met and a submission ...

READ FULL ARTICLE >

MC2 Therapeutics A/S announces completion of recruitment in US Phase 3 trial in Psoriasis Vulgaris

POSTED: April 2, 2018

  • Topline results are expected in Q3 2018

Copenhagen, April 2nd, 2018 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that the patient enrollment for the Phase ...

READ FULL ARTICLE >

Upcoming Events:

September 12th – 16th, 2018

European Academy of Dermatology & Venereology (EADV)

READ MORE >

October 25th, 2018

OIS@AAO – Ophthalmology Innovation Summit

READ MORE >

June 5th – 8th, 2018

Jefferies 2018 Global Healthcare Conference

READ MORE >

May 14th – 16th, 2018

Bio€quity Europe

READ MORE >

January 8th – 11th, 2017

J.P. Morgan 36th Annual Healthcare Conference 2018 (San Francisco)

READ MORE >

November 15th – 16th, 2017

Jefferies 2017 London Healthcare Conference

READ MORE >

November 9th, 2017

OIS@AAO – Ophthalmology Innovation Summit

READ MORE >

© mc2 therapeautics 2016